Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Ischemic Heart Disease

Free Subscription Articles published in J Cardiovasc Pharmacol Retrieve available abstracts of 127 articles: HTML format

Single Articles

September 2023
1. LIN L, Zicheng L, Shaohua G
   Post-acute myocardial infarction heart failure core genes and relevant signaling pathways.
   J Cardiovasc Pharmacol. 2023 Sep 6. doi: 10.1097/FJC.0000000000001481.
   PubMed     Abstract available
   
   
   
2. QIN H, Zhou J
   Myocardial Protection by Desflurane: From Basic Mechanisms to Clinical Applications.
   J Cardiovasc Pharmacol. 2023;82:169-179.
   PubMed     Abstract available
   
   
   August 2023
3. SHAH JT, Shah KT, Femia AN, Lo Sicco KI, et al
   Cardiovascular Risk Management in Patients Treated with JAK Inhibitors.
   J Cardiovasc Pharmacol. 2023 Aug 10. doi: 10.1097/FJC.0000000000001470.
   PubMed     Abstract available
   
   
   
4. KAPLAN A, Lakkis B, El-Samadi L, Karaayvaz EB, et al
   Cooling Down Inflammation in the Cardiovascular System via the Nicotinic Acetylcholine Receptor.
   J Cardiovasc Pharmacol. 2023 Aug 4. doi: 10.1097/FJC.0000000000001455.
   PubMed     Abstract available
   
   
   
5. CHEN R, Zhang Y, Zhou H, Hu Y, et al
   SGLT2 inhibitor-pretreated macrophage transplantation improves adverse ventricular remodeling after acute myocardial infarction.
   J Cardiovasc Pharmacol. 2023 Aug 3. doi: 10.1097/FJC.0000000000001466.
   PubMed     Abstract available
   
   
   
6. MORONI F, Abbate A
   Anti-inflammatory (colchicine) treatment for secondary prevention in coronary artery disease: a milestone has been met.
   J Cardiovasc Pharmacol. 2023 Aug 3. doi: 10.1097/FJC.0000000000001467.
   PubMed    
   
   
   
7. ALGAIDI SH, Alghamdi DI, Algheffari SG, Alzahrani RA, et al
   Long-term cardiovascular adverse events induced by fluoroquinolones: A retrospective case-control study.
   J Cardiovasc Pharmacol. 2023 Aug 1. doi: 10.1097/FJC.0000000000001459.
   PubMed     Abstract available
   
   
   
8. BORGI M, Peruzzi M, Biondi-Zoccai G, Versaci F, et al
   Trimetazidine after coronary revascularization: much ado about nothing?
   J Cardiovasc Pharmacol. 2023 Aug 1. doi: 10.1097/FJC.0000000000001462.
   PubMed    
   
   
   
9. TIAN MY, Wang XY, Chen F, Guo YF, et al
   Comparison of Ticagrelor Monotherapy and Ticagrelor plus Aspirin Among Patients with Acute Coronary Syndrome Combined with High-Risk of Gastrointestinal Bleeding after PCI: a Retrospective Cohort Study.
   J Cardiovasc Pharmacol. 2023 Aug 1. doi: 10.1097/FJC.0000000000001461.
   PubMed     Abstract available
   
   
   
10. TOPRAK K, Kaplangoray M, Memioglu T, Inanir M, et al
    The Relationship Between Nitrate-Induced Headache and -Blood Viscosity: An Observational Prospective Study.
    J Cardiovasc Pharmacol. 2023;82:162-168.
    PubMed     Abstract available
    
    
    
11. WANG CC, Zhao Q, Guo BY, Hao J, et al
    The Plasma Concentration of Ticagrelor and Aspirin as a Predictor of Bleeding Complications in Chinese Acute Coronary Syndrome Patients With Dual Antiplatelet Therapy: A Prospective Observational Study.
    J Cardiovasc Pharmacol. 2023;82:148-156.
    PubMed     Abstract available
    
    
    
12. GOEL H, Carey M, Elshaikh A, Krinock M, et al
    Cardioprotective and Antianginal Efficacy of Nicorandil: A Comprehensive Review.
    J Cardiovasc Pharmacol. 2023;82:69-85.
    PubMed     Abstract available
    
    
    
13. XIAO Z, Guan L, Shi H, Yu Y, et al
    Trimetazidine Affects Mitochondrial Calcium Uniporter Expression to Restore Ischemic Heart Function via Reactive Oxygen Species/NFkappaB Pathway Inhibition.
    J Cardiovasc Pharmacol. 2023;82:104-116.
    PubMed     Abstract available
    
    
    
14. LI W, Luo Y, Huang Z, Shen S, et al
    Costunolide Protects Myocardium From Ischemia Reperfusion Injury by Inhibiting Oxidative Stress Through Nrf2/Keap1 Pathway Activation.
    J Cardiovasc Pharmacol. 2023;82:117-127.
    PubMed     Abstract available
    
    
    July 2023
15. LI Y, Zhang J, He J, Chen X, et al
    Association of the L3MBTL3 rs1125970 and rs4897367 gene polymorphisms with coronary heart disease susceptibility in the Chinese population: a case-control study.
    J Cardiovasc Pharmacol. 2023 Jul 31. doi: 10.1097/FJC.0000000000001464.
    PubMed     Abstract available
    
    
    
16. WHITE RT, Sirek ME, Marrs JC
    Oral Oncolytics and Cardiovascular Risk Management and Monitoring.
    J Cardiovasc Pharmacol. 2023 Jul 27. doi: 10.1097/FJC.0000000000001458.
    PubMed     Abstract available
    
    
    
17. PARK S, Chang J, Hong SP, Jin ES, et al
    Impact of Trimetazidine on the Incident Heart Failure Following Coronary Artery Revascularization.
    J Cardiovasc Pharmacol. 2023 Jul 11. doi: 10.1097/FJC.0000000000001453.
    PubMed     Abstract available
    
    
    
18. KIM HY, Mok J, Kim JY, Jeon D, et al
    Effect of Angiotensin Receptor Blocker Dose in Myocardial Infarction With Preserved Left Ventricular Systolic Function.
    J Cardiovasc Pharmacol. 2023;82:52-60.
    PubMed     Abstract available
    
    
    May 2023
19. FU C, Yu S, Liu Z, Wang J, et al
    PFKFB2 inhibits ferroptosis in myocardial ischemia/reperfusion injury through AMPK activation.
    J Cardiovasc Pharmacol. 2023 May 5. doi: 10.1097/FJC.0000000000001437.
    PubMed     Abstract available
    
    
    
20. HASSAN AE, Hadhoud S, Elmahdi E, Elkattawy HA, et al
    Potential Cardioprotective Role of Menaquinone-4 Against Cardiac Ischemia-reperfusion Injury.
    J Cardiovasc Pharmacol. 2023;81:381-388.
    PubMed     Abstract available
    
    
    April 2023
21. WANG S, Mu Y, Tan L, Hao J, et al
    Efficacy and safety of different dosing regimens of colchicine in patients with coronary artery disease: a network meta-analysis of 15 randomized controlled trials.
    J Cardiovasc Pharmacol. 2023 Apr 6. doi: 10.1097/FJC.0000000000001426.
    PubMed     Abstract available
    
    
    March 2023
22. SPADAFORA L, Crimi G, Porto I, Biondi-Zoccai G, et al
    Statin therapy after myocardial infarction in patients with renal failure: the longer, the merrier!
    J Cardiovasc Pharmacol. 2023 Mar 16. doi: 10.1097/FJC.0000000000001420.
    PubMed     Abstract available
    
    
    
23. ZHANG D, Mi Z, Peng J, Yang T, et al
    Non-alcoholic fatty liver disease as an emerging risk factor and potential intervention target for atherosclerotic cardiovascular diseases.
    J Cardiovasc Pharmacol. 2023 Mar 13. doi: 10.1097/FJC.0000000000001418.
    PubMed     Abstract available
    
    
    
24. KUANG N, Shu B, Yang F, Li S, et al
    TRAIL or TRAIL-R2 as a predictive biomarker for mortality or cardiovascular events: A systematic review and meta-analysis.
    J Cardiovasc Pharmacol. 2023 Mar 9. doi: 10.1097/FJC.0000000000001415.
    PubMed     Abstract available
    
    
    February 2023
25. LACOURSIERE L, Woodruff AE, Mills K, Chilbert MR, et al
    A Retrospective Review of Cardiogenic Shock Development in Patients with ST-elevation Myocardial Infarction (STEMI) and Percutaneous Coronary Intervention (PCI) Receiving Early Beta-Blockers.
    J Cardiovasc Pharmacol. 2023 Feb 23. doi: 10.1097/FJC.0000000000001412.
    PubMed     Abstract available
    
    
    
26. ROSTAMZADEH F, Jafarinejad-Farsangi S, Ansari-Asl Z, Farrokhi MS, et al
    Treatment for myocardial infarction: in vivo evaluation of curcumin-loaded PEGylated-GQDs nanoparticles.
    J Cardiovasc Pharmacol. 2023 Feb 23. doi: 10.1097/FJC.0000000000001410.
    PubMed     Abstract available
    
    
    
27. MORONI F, Ayers MP, Dixon DL, Abbate A, et al
    PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 INHIBITORS (PCSK9i) IN ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: REAL-WORLD DATA WELCOME.
    J Cardiovasc Pharmacol. 2023 Feb 23. doi: 10.1097/FJC.0000000000001411.
    PubMed    
    
    
    
28. CORCIONE N, Biondi-Zoccai G, Castellani V, Carnevale R, et al
    Vitamin D3 and omega-3 fatty acids: A new approach for cardiovascular prevention.
    J Cardiovasc Pharmacol. 2023 Feb 15. doi: 10.1097/FJC.0000000000001407.
    PubMed     Abstract available
    
    
    
29. KHEDRI M, Szummer K, Lundman P, Jernberg T, et al
    Statin treatment intensity, discontinuation and long-term outcome in patients with acute myocardial infarction and impaired kidney function.
    J Cardiovasc Pharmacol. 2023 Feb 1. doi: 10.1097/FJC.0000000000001402.
    PubMed     Abstract available
    
    
    
30. RUSSO V, Fabiani D, Leonardi S, Attena E, et al
    Dual Pathway Inhibition with Rivaroxaban and Aspirin Reduces Inflammatory Biomarkers in Atherosclerosis.
    J Cardiovasc Pharmacol. 2023;81:129-133.
    PubMed     Abstract available
    
    
    December 2022
31. PENG W, Zhang Y, Lin B, Lin Y, et al
    Clinical outcomes of individualized antiplatelet therapy based on platelet function test in patients after percutaneous coronary intervention: a systematic review and meta-analysis.
    J Cardiovasc Pharmacol. 2022 Dec 21. doi: 10.1097/FJC.0000000000001393.
    PubMed     Abstract available
    
    
    November 2022
32. PENG W, Zhang Y, Li X, Lin Y, et al
    Efficacy and safety of clopidogrel versus ticagrelor for stabilized patients with acute coronary syndromes after percutaneous coronary intervention: results from a real-world registry in China.
    J Cardiovasc Pharmacol. 2022 Nov 18. doi: 10.1097/FJC.0000000000001381.
    PubMed     Abstract available
    
    
    
33. ALEXOPOULOS D, Dragona VM, Varlamos C, Ktenas D, et al
    One-year outcomes in anticoagulated atrial fibrillation patients undergoing percutaneous coronary intervention: insights from the Greek Antiplatelet Atrial Fibrillation (GRAPE-AF) registry.
    J Cardiovasc Pharmacol. 2022 Nov 18. doi: 10.1097/FJC.0000000000001389.
    PubMed     Abstract available
    
    
    
34. ZHANG H, Jing L, Zhai C, Xiang Q, et al
    The Intestinal Flora Metabolite Trimethylamine Oxide Is Inextricably Linked to Coronary Heart Disease.
    J Cardiovasc Pharmacol. 2022 Nov 18. doi: 10.1097/FJC.0000000000001387.
    PubMed     Abstract available
    
    
    October 2022
35. DEO S, Ueda P, Sheikh MA, Altarabsheh S, et al
    Lipid-lowering in 'very high risk' patients undergoing coronary artery bypass surgery and its projected reduction in risk for recurrent vascular events: A Monte Carlo stepwise simulation approach.
    J Cardiovasc Pharmacol. 2022 Oct 12. pii: 00005344-990000000-00121.
    PubMed     Abstract available
    
    
    
36. SEIJAS-AMIGO J, Cordero A, Fernandez Del Olmo R, Cortez Quiroga GA, et al
    Patients with high cardiovascular risk as candidates to bempedoic acid after treatment with statins, ezetimibe and PCSK9 inhibitors. An estimation and cost-effectiveness analysis.
    J Cardiovasc Pharmacol. 2022 Oct 11. pii: 00005344-990000000-00111.
    PubMed     Abstract available
    
    
    
37. GIORDANO S, Spadafora L, Biondi-Zoccai G, Bernardi M, et al
    Magnitude of low-density lipoprotein reduction and impact on major cardiovascular outcomes.
    J Cardiovasc Pharmacol. 2022 Oct 10. pii: 00005344-990000000-00119.
    PubMed    
    
    
    
38. LA VECCHIA G, Del Buono MG
    Colchicine in Patients With STEMI: More Doubts Than Certainties.
    J Cardiovasc Pharmacol. 2022;80:499.
    PubMed    
    
    
    September 2022
39. MASTER YW, Master QZ, Master HC, Master ZW, et al
    Effects of recombinant human brain natriuretic peptide on atrial fibrillation after coronary artery bypass grafting.
    J Cardiovasc Pharmacol. 2022 Sep 9. pii: 00005344-990000000-00114.
    PubMed     Abstract available
    
    
    
40. JI M, Li Y, Liu Y, Ma G, et al
    Vaspin Ameliorates Cardiac Remodeling by Suppressing Phosphoinositide 3-Kinase/Protein Kinase B Pathway to Improve Oxidative Stress in Heart Failure Rats.
    J Cardiovasc Pharmacol. 2022;80:442-452.
    PubMed     Abstract available
    
    
    
41. CHEN JY, Li T, Wang JL, Wang ZL, et al
    Protective Effects and Mechanisms of Melatonin on Stress Myocardial Injury in Rats.
    J Cardiovasc Pharmacol. 2022;80:417-429.
    PubMed     Abstract available
    
    
    August 2022
42. ENNEZAT PV, Guerbaai RA, Marechaux S, Le Jemtel TH, et al
    Extent of LDL-cholesterol Reduction and All-cause and Cardiovascular Mortality Benefit: a Systematic Review and Meta-analysis.
    J Cardiovasc Pharmacol. 2022 Aug 23. pii: 00005344-990000000-00106.
    PubMed     Abstract available
    
    
    
43. YANG S, Shen W, Zhang HZ, Wang CX, et al
    Efficacy and Safety of Finerenone for Prevention of Cardiovascular Events in Type 2 Diabetes Mellitus with Chronic Kidney Disease: A Meta-analysis of Randomized Controlled Trials.
    J Cardiovasc Pharmacol. 2022 Aug 23. pii: 00005344-990000000-00107.
    PubMed     Abstract available
    
    
    
44. AMIN G, Massoud G, Fares S, Booz GW, et al
    Colchicine and acute coronary syndromes: a new trick for an old drug?
    J Cardiovasc Pharmacol. 2022 Aug 18. pii: 00005344-990000000-00100.
    PubMed    
    
    
    
45. HUI J, Bai T, Liang L, He Q, et al
    Efficacy and Safety of Shortened Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention: A Meta-analysis of Randomized Controlled Trials.
    J Cardiovasc Pharmacol. 2022 Aug 15. pii: 00005344-990000000-00094.
    PubMed     Abstract available
    
    
    
46. BURASHNIKOV A, Abbate A, Booz GW
    Cardiovascular complications of anti-cancer therapy: a developing storm in medicine.
    J Cardiovasc Pharmacol. 2022 Aug 15. pii: 00005344-990000000-00095.
    PubMed    
    
    
    
47. ANTO S, Sathish V, Sun C, O'Rourke ST, et al
    Apelin-Induced Relaxation of Coronary Arteries is Impaired in a Model of Second-Hand Cigarette Smoke Exposure.
    J Cardiovasc Pharmacol. 2022 Aug 11. pii: 00005344-990000000-00093.
    PubMed     Abstract available
    
    
    
48. CALCAGNO S, Corcione N, Biondi-Zoccai G, Giordano A, et al
    De-Escalation of Dual Antiplatelet Therapy: Will We Ever Get to the Right Method?
    J Cardiovasc Pharmacol. 2022;80:203-205.
    PubMed    
    
    
    July 2022
49. PEPE M, Napoli G, Biondi-Zoccai G, Giordano A, et al
    Anti-inflammatory therapy for acute coronary syndromes: is it time for a shift in the treatment paradigm?
    J Cardiovasc Pharmacol. 2022 Jul 20. pii: 00005344-990000000-00085.
    PubMed    
    
    
    
50. SHARMA P, Sharma N
    Advances in Nano-formulated Polyphenols for Protection against Cardiovascular diseases.
    J Cardiovasc Pharmacol. 2022 Jul 18. pii: 00005344-990000000-00082.
    PubMed     Abstract available
    
    
    
51. VAN TASSELL BW, Wohlford GF, Del Buono MG, Damonte JI, et al
    Safety, tolerability and effects of a single subcutaneous administration of SP16-a SERPIN-like, small peptide agonist of the Low-Density Lipoprotein-like Receptor 1 -on the acute inflammatory response in patients with ST-segment elevation Myocardial I
    J Cardiovasc Pharmacol. 2022 Jul 12. pii: 00005344-990000000-00079.
    PubMed     Abstract available
    
    
    
52. YANG G, Gai X, Han M, Gao F, et al
    Aberrant circulating SNHG1 serves as a biomarker to distinguish acute myocardial infarction and construction of a risk model for secondary heart failure.
    J Cardiovasc Pharmacol. 2022 Jul 11. pii: 00005344-990000000-00043.
    PubMed    
    
    
    
53. AKANDE O, Chen Q, Cholyway R, Toldo S, et al
    Modulation of Mitochondrial Respiration During Early Reperfusion Reduces Cardiac Injury in Donation After Circulatory Death Hearts.
    J Cardiovasc Pharmacol. 2022;80:148-157.
    PubMed     Abstract available
    
    
    June 2022
54. HOSSEINI SH, Talasaz AH, Alidoosti M, Tajdini M, et al
    Pre-Procedural Colchicine in Patients with Acute ST-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention: a Randomized Controlled Trial (PodCAST-PCI).
    J Cardiovasc Pharmacol. 2022 Jun 22. pii: 00005344-990000000-00067.
    PubMed     Abstract available
    
    
    
55. BAO YL, Gu LF, Du C, Wang YX, et al
    Evaluating the utility of colchicine in acute coronary syndrome: A systematic review and meta-analysis.
    J Cardiovasc Pharmacol. 2022 Jun 22. pii: 00005344-990000000-00068.
    PubMed     Abstract available
    
    
    May 2022
56. SOTHIVELR V, Hasan MY, Saffian SM, Zainalabidin S, et al
    Revisiting miRNA-21 as a Therapeutic Strategy for Myocardial Infarction: A Systematic Review.
    J Cardiovasc Pharmacol. 2022 May 20. pii: 00005344-990000000-00055.
    PubMed     Abstract available
    
    
    
57. LYCOURAS MM, Clark CM, Mills K, Gupta A, et al
    Early versus late administration of P2Y12 inhibitors in non-ST segment elevation myocardial infarction and delayed cardiac catherization.
    J Cardiovasc Pharmacol. 2022 May 13. pii: 00005344-990000000-00051.
    PubMed     Abstract available
    
    
    
58. ZHONG PY, Shang YS, Bai N, Ma Y, et al
    Dual antiplatelet therapy after drug-eluting stents implantation in East Asians: a network meta-analysis of randomized controlled trials.
    J Cardiovasc Pharmacol. 2022 May 6. pii: 00005344-990000000-00042.
    PubMed     Abstract available
    
    
    
59. SHANG YS, Zhong PY, Ma Y, Bai N, et al
    Efficacy and Safety of Proton Pump Inhibitors in Patients with Coronary Artery Diseases Receiving Oral Antiplatelet Agents and/or Anticoagulants: A Systematic Review and Meta-Analysis.
    J Cardiovasc Pharmacol. 2022 May 4. pii: 00005344-990000000-00036.
    PubMed     Abstract available
    
    
    
60. XUE K, Chen S, Chai J, Yan W, et al
    Upregulation of Periostin Through CREB Participates in Myocardial Infarction-induced Myocardial Fibrosis.
    J Cardiovasc Pharmacol. 2022;79:687-697.
    PubMed     Abstract available
    
    
    April 2022
61. DENNY O, Woodruff AE, Mills K, Chilbert MR, et al
    Comparison of ischemic and bleeding events between short versus long duration tirofiban regimens in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
    J Cardiovasc Pharmacol. 2022 Apr 29. pii: 00005344-990000000-00037.
    PubMed     Abstract available
    
    
    
62. GITTO M, Kotinas AS, Terzi R, Oliva A, et al
    Biochemical efficacy of sodium-glucose cotransporter 2 inhibitors by cardiovascular risk profile and volume status in a real-world diabetic population.
    J Cardiovasc Pharmacol. 2022 Apr 14. pii: 00005344-990000000-00025.
    PubMed     Abstract available
    
    
    
63. SHAN C, Degryse B, Tolan P, Custaud MA, et al
    Pleiotropic effects of Icariside II on the cardiovascular system: Novel applications of ethnopharmacology in targeting vascular remodelling.
    J Cardiovasc Pharmacol. 2022 Apr 12. pii: 00005344-990000000-00024.
    PubMed    
    
    
    
64. BAI N, Ma Y, Niu Y, Zhong PY, et al
    Efficacy and safety of de-escalation of antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome: a meta-analysis of randomized clinical trials.
    J Cardiovasc Pharmacol. 2022 Apr 8. pii: 00005344-990000000-00022.
    PubMed     Abstract available
    
    
    
65. ADEVA-ANDANY MM, Fernandez-Fernandez C, Carneiro-Freire N, Castro-Quintela E, et al
    Cardiovascular protection associated with cilostazol, colchicine and target of rapamycin inhibitors.
    J Cardiovasc Pharmacol. 2022 Apr 6. pii: 00005344-990000000-00019.
    PubMed     Abstract available
    
    
    
66. DAI H, Zhao N, Zheng Y
    CircLDLR modulates the proliferation and apoptosis of vascular smooth muscle cells in coronary artery disease through miR-26-5p/KDM6A axis.
    J Cardiovasc Pharmacol. 2022 Apr 6. pii: 00005344-990000000-00018.
    PubMed     Abstract available
    
    
    
67. AKYILDIZ AG, Biondi-Zoccai G, De Biase D
    Impact of the Gastrointestinal Tract Microbiota on Cardiovascular Health and Pathophysiology.
    J Cardiovasc Pharmacol. 2022 Apr 6. pii: 00005344-990000000-00021.
    PubMed     Abstract available
    
    
    
68. VLACHAKIS PK, Varlamos C, Benetou DR, Kanakakis I, et al
    Periprocedural Antithrombotic Treatment in Complex Percutaneous Coronary Intervention.
    J Cardiovasc Pharmacol. 2022;79:407-419.
    PubMed     Abstract available
    
    
    
69. DENG X, Liu Y, Xu Z, Wang Z, et al
    lncRNA Nuclear Factor of Activated T Cells Knockdown Alleviates Hypoxia/Reoxygenation-induced Cardiomyocyte Apoptosis by Upregulating HIF-1alpha Expression.
    J Cardiovasc Pharmacol. 2022;79:479-488.
    PubMed     Abstract available
    
    
    March 2022
70. BROMAGE DI, Pareek N, Cannata A, Ameri P, et al
    Targeting inflammation after myocardial infarction - another piece of the puzzle.
    J Cardiovasc Pharmacol. 2022 Mar 15. pii: 00005344-990000000-00009.
    PubMed    
    
    
    
71. ZHOU S, Liu P, Zhang G, Cheng Z, et al
    HDAC1 depletion alleviates coronary heart disease via the microRNA-182-mediated TGF-beta/Smad signaling pathway.
    J Cardiovasc Pharmacol. 2022 Mar 11. pii: 00005344-990000000-00008.
    PubMed     Abstract available
    
    
    
72. HU MJ, Tan JS, Gao XJ, Yang JG, et al
    De-Escalation of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome: An Updated Meta-Analysis and Trial Sequential Analysis of 21 studies and 38741 patients.
    J Cardiovasc Pharmacol. 2022 Mar 4. pii: 00005344-990000000-00029.
    PubMed     Abstract available
    
    
    
73. POLETTO BONETTO JH, Luz de Castro A, Fernandes RO, Corssac GB, et al
    Sulforaphane Effects on Cardiac Function and Calcium-Handling-Related Proteins in 2 Experimental Models of Heart Disease: Ischemia-Reperfusion and Infarction.
    J Cardiovasc Pharmacol. 2022;79:325-334.
    PubMed     Abstract available
    
    
    February 2022
74. BERGH N, Myredal A, Nivedahl P, Petzold M, et al
    Efficacy and safety of clopidogrel versus ticagrelor as part of dual antiplatelet therapy in acute coronary syndrome - a systematic review and meta-analysis.
    J Cardiovasc Pharmacol. 2022 Feb 14. pii: 00005344-900000000-98046.
    PubMed     Abstract available
    
    
    
75. XU H, Tilley DG
    Pepducin-mediated GPCR signaling in the cardiovascular system.
    J Cardiovasc Pharmacol. 2022 Feb 11. pii: 00005344-900000000-98051.
    PubMed     Abstract available
    
    
    
76. DEL BUONO MG, Damonte JI, Chiabrando JG, Markley R, et al
    Effect of IL-1 Blockade with Anakinra on Heart Failure Outcomes in Patients with Anterior versus Non-Anterior STEMI.
    J Cardiovasc Pharmacol. 2022 Feb 11. pii: 00005344-900000000-98049.
    PubMed     Abstract available
    
    
    
77. BEAVERS CJ, Effoe SA, Dobesh PP
    Selatogrel: A Novel Subcutaneous P2Y12 Inhibitor.
    J Cardiovasc Pharmacol. 2022;79:161-167.
    PubMed     Abstract available
    
    
    January 2022
78. MA Y, Zhong PY, Shang YS, Bai N, et al
    Comparison of ticagrelor with clopidogrel in East Asian patients with acute coronary syndrome: a systematic review and meta-analysis of randomized clinical trials.
    J Cardiovasc Pharmacol. 2022 Jan 27. pii: 00005344-900000000-98056.
    PubMed     Abstract available
    
    
    
79. CIZMAROVA B, Evinova A, Racay P, Birkova A, et al
    The effect of oestrogen supplementation on antioxidant enzymes and mitochondrial respiratory function after myocardial infarction of ovariectomized rats.
    J Cardiovasc Pharmacol. 2022 Jan 21. pii: 00005344-900000000-98057.
    PubMed     Abstract available
    
    
    
80. KIM Y, Byun S, Kim HY, Kim DB, et al
    Long-term beta-blocker therapy after myocardial infarction without heart failure in the reperfusion era - systemic review and meta-analysis.
    J Cardiovasc Pharmacol. 2022 Jan 18. pii: 00005344-900000000-98062.
    PubMed     Abstract available
    
    
    
81. ZOU HT, Yang GH, Cai YJ, Chen H, et al
    Are high- or low-dose SGLT2 inhibitors associated with cardiovascular and respiratory adverse events? A meta-analysis.
    J Cardiovasc Pharmacol. 2022 Jan 18. pii: 00005344-900000000-98061.
    PubMed     Abstract available
    
    
    
82. AL-ANI MA, Murray MR, Taha MB, Meece L, et al
    Impact of Laparoscopic Sleeve Gastrectomy on Cardiovascular Pharmacotherapy in Left Ventricular Assist Device Patients.
    J Cardiovasc Pharmacol. 2022 Jan 17. pii: 00005344-900000000-98060.
    PubMed     Abstract available
    
    
    December 2021
83. WANG K, Tang R, Wang S, Xiong Y, et al
    Isoform-selective HDAC Inhibitor Mocetinostat (MGCD0103) Alleviates Myocardial Ischemia/Reperfusion Injury via Mitochondrial Protection through the HDACs/CREB/PGC-1alpha Signaling Pathway.
    J Cardiovasc Pharmacol. 2021 Dec 28. pii: 00005344-900000000-98074.
    PubMed     Abstract available
    
    
    
84. LIU X, Qi K, Gong Y, Long X, et al
    Ferulic Acid Alleviates Myocardial Ischemia Reperfusion Injury Via Upregulating AMPKalpha2 Expression-Mediated Ferroptosis Depression.
    J Cardiovasc Pharmacol. 2021;79:489-500.
    PubMed     Abstract available
    
    
    
85. SHRESTHA DB, Budhathoki P, Sedhai YR, Khadka M, et al
    Colchicine for patients with coronary artery disease: A Systematic Review and Meta-Analysis.
    J Cardiovasc Pharmacol. 2021 Dec 13. pii: 00005344-900000000-98085.
    PubMed     Abstract available
    
    
    
86. BRAGA CL, Acquarone M, da C Arona V, Osorio BS, et al
    Can epigenetics help solve the puzzle between concomitant cardiovascular injury and severity of COVID-19?
    J Cardiovasc Pharmacol. 2021 Dec 10. pii: 00005344-900000000-98080.
    PubMed     Abstract available
    
    
    
87. GODO S, Takahashi J, Yasuda S, Shimokawa H, et al
    Endothelium in Coronary Macrovascular and Microvascular Diseases.
    J Cardiovasc Pharmacol. 2021;78.
    PubMed     Abstract available
    
    
    
88. SAYED-PATHAN NI, Kumar P, Paknikar KM, Gajbhiye V, et al
    MicroRNAs: A Neoteric Approach to Understand Pathogenesis, Diagnose, and Treat Myocardial Infarction.
    J Cardiovasc Pharmacol. 2021;78:773-781.
    PubMed     Abstract available
    
    
    
89. YANG J, Xiang Z, Zhang J, Yang J, et al
    miR-24 Alleviates MI/RI by Blocking the S100A8/TLR4/MyD88/NF-kB Pathway.
    J Cardiovasc Pharmacol. 2021;78:847-857.
    PubMed     Abstract available
    
    
    November 2021
90. MA Y, Zhong PY, Shang YS, Bai N, et al
    Efficacy and Safety of Short-Term Dual Antiplatelet Therapy in East Asians: A Systematic Review and a Meta-Analysis of Randomized Clinical Trials.
    J Cardiovasc Pharmacol. 2021;79:264-272.
    PubMed     Abstract available
    
    
    
91. TEMIZ-RESITOGLU M, Guden DS, Senol SP, Vezir O, et al
    Pharmacological inhibition of mTOR attenuates DOCA-salt-induced hypertension and related pathophysiology: regulation of oxidative stress, inflammation and cardiovascular hypertrophy in male rats.
    J Cardiovasc Pharmacol. 2021 Nov 23. pii: 00005344-900000000-98105.
    PubMed     Abstract available
    
    
    
92. WINGLER LM, Feld AP
    Nanobodies as probes and modulators of cardiovascular GPCRs.
    J Cardiovasc Pharmacol. 2021 Nov 19. pii: 00005344-900000000-98107.
    PubMed     Abstract available
    
    
    
93. HIJAZI Y, Karkabi B, Feldman M, Malca B, et al
    Bridging care transition after hospitalization for atrial fibrillation and coronary interventions.
    J Cardiovasc Pharmacol. 2021 Nov 16. pii: 00005344-900000000-98113.
    PubMed     Abstract available
    
    
    
94. GRAGNANO F, Calabro P, Cattano D
    CYP2C19 Genotyping to Risk Stratify Patients After Coronary Stent Implantation: Time for a Personalized Approach?
    J Cardiovasc Pharmacol. 2021 Nov 16. pii: 00005344-900000000-98112.
    PubMed    
    
    
    
95. CATURANO A, Spiezia S, Sasso FC
    Statin effect on Major Adverse Cardiac Events after Percutaneous Coronary Intervention in Patients on Haemodialysis.
    J Cardiovasc Pharmacol. 2021 Nov 3. pii: 00005344-900000000-98118.
    PubMed    
    
    
    
96. LI X, Dang Y
    Inhibition of GARS1-DT Protects Against Hypoxic Injury in H9C2 Cardiomyocytes via Sponging miR-212-5p.
    J Cardiovasc Pharmacol. 2021;78:e714-e721.
    PubMed     Abstract available
    
    
    October 2021
97. ZHANG Y, Zhao X, Ye Y, Li Q, et al
    Clinical Outcomes after Percutaneous Coronary Intervention Over Time on the Basis of CYP2C19 Polymorphisms.
    J Cardiovasc Pharmacol. 2021 Oct 26. pii: 00005344-900000000-98125.
    PubMed     Abstract available
    
    
    
98. MELITA H, Manolis AA, Manolis TA, Manolis AS, et al
    Lipoprotein (a) and Cardiovascular Disease: A Missing Link for Premature Atherosclerotic Heart Disease and/or Residual Risk.
    J Cardiovasc Pharmacol. 2021 Oct 20. pii: 00005344-900000000-98128.
    PubMed     Abstract available
    
    
    
99. HORIKOSHI T, Nakamura T, Yoshizaki T, Nakamura J, et al
    Stratification Analysis of Statin Effect on Major Adverse Cardiac Events after Percutaneous Coronary Intervention in Patients on Hemodialysis.
    J Cardiovasc Pharmacol. 2021 Oct 6. pii: 00005344-900000000-98138.
    PubMed     Abstract available
    
    
    
100. ASSMANN AK, Goschmer D, Sugimura Y, Chekhoeva A, et al
     A role for peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonists in counteracting the degeneration of cardiovascular grafts.
     J Cardiovasc Pharmacol. 2021 Oct 4. pii: 00005344-900000000-98134.
     PubMed     Abstract available
     
     
     
101. WANG X, Sun Q, Hu W
     Carvedilol Protects Against the H2O2-induced Cell Damages in Rat Myoblasts by Regulating the Circ_NFIX/miR-125b-5p/TLR4 Signal Axis.
     J Cardiovasc Pharmacol. 2021;78:604-614.
     PubMed     Abstract available
     
     
     September 2021
102. DU X, Ma Z, Li L, Zhong X, et al
     Nicorandil Decreases Renal Injury in Patients With Coronary Heart Disease Complicated With Type I Cardiorenal Syndrome.
     J Cardiovasc Pharmacol. 2021;78:e675-e680.
     PubMed     Abstract available
     
     
     
103. LOPEZ AE, Bauza MDR, Cuniberti L, Crottogini AJ, et al
     Gene Therapy: Targeting Cardiomyocyte Proliferation to Repopulate the Ischemic Heart.
     J Cardiovasc Pharmacol. 2021;78:346-360.
     PubMed     Abstract available
     
     
     
104. ZHANG DM, Chen SL
     Potential Mechanisms of In-stent Neointimal Atherosclerotic Plaque Formation.
     J Cardiovasc Pharmacol. 2021;78:388-393.
     PubMed     Abstract available
     
     
     August 2021
105. DIAZ-CANESTRO C, Xu A
     The impact of different adipose depots on cardiovascular disease.
     J Cardiovasc Pharmacol. 2021 Aug 19. pii: 00005344-900000000-98098.
     PubMed     Abstract available
     
     
     
106. LIU XW, Lu MK, Zhong HT, Liu JJ, et al
     Panax Notoginseng Saponins Protect H9c2 Cells From Hypoxia-reoxygenation Injury Through the Forkhead Box O3a Hypoxia-inducible Factor-1 Alpha Cell Signaling Pathway.
     J Cardiovasc Pharmacol. 2021;78:e681-e689.
     PubMed     Abstract available
     
     
     
107. JI P, Song X, Lv Z
     Knockdown of circ_0004104 Alleviates Oxidized Low-Density Lipoprotein-Induced Vascular Endothelial Cell Injury by Regulating miR-100/TNFAIP8 Axis.
     J Cardiovasc Pharmacol. 2021;78:269-279.
     PubMed     Abstract available
     
     
     
108. YUAN M, Wu B, Zhang L, Wang H, et al
     CD40L/CD40 Regulates Adipokines and Cytokines by H3K4me3 Modification in Epicardial Adipocytes.
     J Cardiovasc Pharmacol. 2021;78:228-234.
     PubMed     Abstract available
     
     
     July 2021
109. DEL BUONO MG, Damonte JI, Trankle CR, Bhardwaj H, et al
     Sacubitril/Valsartan for the prevention and treatment post-infarction heart failure: ready to use?
     J Cardiovasc Pharmacol. 2021 Jul 2. pii: 00005344-900000000-98179.
     PubMed    
     
     
     
110. SOLTAN F, Esmaili Dahej M, Yadegari M, Moradi A, et al
     Resveratrol Confers Protection Against Ischemia/Reperfusion Injury by Increase of Angiotensin (1-7) Expression in a Rat Model of Myocardial Hypertrophy.
     J Cardiovasc Pharmacol. 2021;78:e55-e64.
     PubMed     Abstract available
     
     
     
111. YIN CL, Liu X, Wang HX, Yan MC, et al
     Dynamic Changes in Plasma Urotensin II and Its Correlation With Plaque Stability.
     J Cardiovasc Pharmacol. 2021;78:e147-e155.
     PubMed     Abstract available
     
     
     
112. CAI X, Li B, Wang Y, Zhu H, et al
     CircJARID2 Regulates Hypoxia-Induced Injury in H9c2 Cells by Affecting miR-9-5p-Mediated BNIP3.
     J Cardiovasc Pharmacol. 2021;78:e77-e85.
     PubMed     Abstract available
     
     
     
113. CARBONE A, Bottino R, Russo V, D'Andrea A, et al
     Takotsubo Cardiomyopathy as Epiphenomenon of Cardiotoxicity in Patients With Cancer: A Meta-summary of Case Reports.
     J Cardiovasc Pharmacol. 2021;78:e20-e29.
     PubMed     Abstract available
     
     
     June 2021
114. PASCALE JV, Lucchesi PA, Garcia V
     Unraveling the Role of 12- and 20- HETE in Cardiac Pathophysiology: G-Protein-Coupled Receptors, Pharmacological Inhibitors, and Transgenic Approaches.
     J Cardiovasc Pharmacol. 2021;77:707-717.
     PubMed     Abstract available
     
     
     
115. ZHANG Y, Nie H, Li S, Deng Y, et al
     Carbon Monoxide-Saturated Polymerized Placenta Hemoglobin Optimizes Mitochondrial Function and Protects Heart Against Ischemia-Reperfusion Injury.
     J Cardiovasc Pharmacol. 2021;77:814-821.
     PubMed     Abstract available
     
     
     
116. YE G, Wang S, Peng D
     Effects of SGLT2 Inhibitor on Ischemic Events Stemming From Atherosclerotic Coronary Diseases: A Systematic Review and Meta-analysis With Trial Sequential Analysis of Randomized Controlled Trials.
     J Cardiovasc Pharmacol. 2021;77:787-795.
     PubMed     Abstract available
     
     
     May 2021
117. NANDKEOLYAR S, Ryu R, Mohammed A, Cordero-Caban K, et al
     A Review of Inotropes and Inopressors for Effective Utilization in Patients with Acute Decompensated Heart Failure.
     J Cardiovasc Pharmacol. 2021 May 28. pii: 00005344-900000000-98208.
     PubMed     Abstract available
     
     
     
118. MA B, Zhao M, Guo Z
     Circular RNA circ_0010729 Knockdown Attenuates Oxygen-Glucose Deprivation-Induced Human Cardiac Myocytes Injury by miR-338-3p/CALM2 Axis.
     J Cardiovasc Pharmacol. 2021;77:594-602.
     PubMed     Abstract available
     
     
     
119. LIU S, Liao Q, Xu W, Zhang Z, et al
     MiR-129-5p Protects H9c2 Cardiac Myoblasts From Hypoxia/Reoxygenation Injury by Targeting TRPM7 and Inhibiting NLRP3 Inflammasome Activation.
     J Cardiovasc Pharmacol. 2021;77:586-593.
     PubMed     Abstract available
     
     
     April 2021
120. LEE CC, Chen WT, Chen SY, Lee TM, et al
     Taurine Alleviates Sympathetic Innervation by Inhibiting NLRP3 Inflammasome in Postinfarcted Rats.
     J Cardiovasc Pharmacol. 2021;77:745-755.
     PubMed     Abstract available
     
     
     
121. TESTA A, Frati G, Versaci F, Biondi-Zoccai G, et al
     Ischemia-Reperfusion Injury: Can We Stop the Curing-Hurting Paradox?
     J Cardiovasc Pharmacol. 2021;77:427-429.
     PubMed    
     
     
     
122. SIMARD T, Motazedian P, Dhaliwal S, Di Santo P, et al
     Revisiting the Evidence for Dipyridamole in Reducing Restenosis: A Systematic Review and Meta-analysis.
     J Cardiovasc Pharmacol. 2021;77:450-457.
     PubMed     Abstract available
     
     
     
123. DE BIASE D, Biondi-Zoccai G, Versaci F, Frati G, et al
     Management of Chronic Stable Angina: Modern Microbiomedical Research Provides Insights Into Traditional Chinese Medicine Treatments.
     J Cardiovasc Pharmacol. 2021;77:421-423.
     PubMed    
     
     
     March 2021
124. SCHAUER A, Barthel P, Adams V, Linke A, et al
     Pharmacological Pre- and Postconditioning With Levosimendan Protect H9c2 Cardiomyoblasts From Anoxia/Reoxygenation-induced Cell Death via PI3K/Akt Signaling.
     J Cardiovasc Pharmacol. 2021;77:378-385.
     PubMed     Abstract available
     
     
     
125. WANG H, Pang W, Xu X, You B, et al
     Cryptotanshinone Attenuates Ischemia/Reperfusion-induced Apoptosis in Myocardium by Upregulating MAPK3.
     J Cardiovasc Pharmacol. 2021;77:370-377.
     PubMed     Abstract available
     
     
     
126. AIMO A, Egea OI, Emdin M, Bayes-Genis A, et al
     Overlapping Effects of miR-21 Inhibition and Drugs for Idiopathic Pulmonary Fibrosis: Rationale for Repurposing Nintedanib as a Novel Treatment for Ischemia/Reperfusion Injury.
     J Cardiovasc Pharmacol. 2021;77:332-333.
     PubMed     Abstract available
     
     
     February 2021
127. ZHAO X, Chen Y, Li L, Zhai J, et al
     Effect of DLT-SML on Chronic Stable Angina Through Ameliorating Inflammation, Correcting Dyslipidemia, and Regulating Gut Microbiota.
     J Cardiovasc Pharmacol. 2021;77:458-469.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Ischemic Heart Disease is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: